US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Vigil Neuroscience, Inc.

< Previous 1 2 Next >
News headline image
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers SNY VIGL
News headline image
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Upcoming September Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present in Upcoming June Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
News headline image
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
< Previous 1 2 Next >